Your browser doesn't support javascript.
loading
Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.
Li, Xiao-Zheng; Li, Ya-Wei; Huang, Cheng-Yang; Liu, Jia-Ling; Liu, Run-Ben; Zhang, Zhi-Xin; Yan, Jin-Zhu; Zhang, Chao.
Affiliation
  • Li XZ; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Li YW; Department of Medical, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Huang CY; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Liu JL; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Liu RB; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Zhang ZX; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Yan JZ; Department of Gynaecology and Obstetrics, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Zhang C; Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Ann Med ; 56(1): 2392882, 2024 Dec.
Article in En | MEDLINE | ID: mdl-39155852
ABSTRACT

BACKGROUND:

Systemic lupus erythematosus (SLE), an extensive autoimmune disorder, compromises viral resistance and alters immune responses post respiratory virus vaccines. This study aims to assess immune response levels and safety in SLE patients following respiratory virus vaccines.

METHODS:

Extensive searches, until 1 March 2024, were conducted using PubMed, EMBASE, and Cochrane Library. Outcomes, encompassing seroconversion rate (SCR), antibody and IgG titers, neutralizing antibodies, anti-spike antibodies, anti-receptor binding domain (RBD) IgG, and adverse events, were appraised.

RESULTS:

Sixteen articles, comprising 25 observational studies, were included. SLE patients exhibited lower SCR (OR = 0.42, 95%CI 0.26 to 0.69), antibody titers (SMD=-2.84, 95%CI -3.36 to -1.61), and neutralizing antibodies (OR = 0.27, 95%CI 0.13 to 0.56) compared to the healthy population post respiratory virus vaccines. Notably, differences were statistically insignificant for anti-RBD IgG (OR = 1.75, 95%CI 0.10 to 29.42), IgG titers (SMD=-2.54, 95%CI -5.57 to -0.49), anti-spike antibodies (OR = 0.35, 95%CI 0.08 to 1.53), injection site discomfort (OR = 1.03, 95%CI 0.52 to 2.06), fatigue (OR = 1.23, 95%CI 0.74 to 2.03), fever (OR = 1.02, 95%CI 0.64 to 1.63), localized reactions (OR = 0.69, 95%CI 0.37 to 1.30), systemic reactions (OR = 1.00, 95%CI 0.59 to 1.69), allergic reactions (OR = 5.11, 95%CI 0.24 to 107.10), self-reported vaccination-related adverse events (OR = 1.61, 95%CI 0.56 to 4.63), and disease flares after vaccination (OR = 1.00, 95%CI 0.14 to 7.28).

CONCLUSION:

Despite the reduced immune response and host protection in SLE patients post-Corona Virus Disease 2019 (COVID-19) and influenza vaccines compared to the healthy population, safety profiles are comparable. Therefore, it is recommended that SLE patients receive COVID-19 and influenza viral vaccines to fortify their resistance.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Observational Studies as Topic / Immunity, Humoral / Lupus Erythematosus, Systemic / Antibodies, Viral Limits: Female / Humans / Male Language: En Journal: Ann Med Journal subject: MEDICINA Year: 2024 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Observational Studies as Topic / Immunity, Humoral / Lupus Erythematosus, Systemic / Antibodies, Viral Limits: Female / Humans / Male Language: En Journal: Ann Med Journal subject: MEDICINA Year: 2024 Document type: Article Affiliation country: China